Home / Market News / $BBIO
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

TD Cowen Maintains Buy Rating on BridgeBio Pharma, Lowers Price Target

Oct 30, 2026, 10:03 PM UTC · Primary ticker $BBIO

TD Cowen maintained its 'Buy' rating on BridgeBio Pharma but reduced its price target from $110 to $100. This adjustment reflects recent market activity and analyst coverage, suggesting a slightly less optimistic near-term outlook for the company's stock.

TD Cowen, a prominent investment bank, reiterated its 'Buy' rating for BridgeBio Pharma, indicating continued confidence in the company's long-term prospects. However, the simultaneous reduction of the price target from $110 to $100, a 9.1% decrease, signals a recalibration of near-term valuation expectations. This adjustment likely stems from recent market dynamics or updated analyst models regarding the biopharmaceutical sector or BridgeBio specifically. For traders, this presents a mixed signal: the maintained 'Buy' suggests underlying strength, but the lower price target could exert downward pressure on the stock in the short term, potentially leading to a slight dip or slower growth. The key risk is whether other analysts follow suit, further dampening sentiment, while the opportunity lies in buying on any dip if the long-term 'Buy' thesis remains strong.

$BBIO negative Price target lowered
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.